Home
Stocks Trading
Analyst Snapshot
Financial Scores
Market Summary

Inhibikase Therapeutics Inc (NASDAQ: IKT)

What Are the Chances of Inhibikase Therapeutics Inc (IKT) Stagnating? Here is the INSIGHT

December 26, 2025

Kenneth Phillips

Inhibikase Therapeutics Inc (IKT)’s stock is trading at $1.81 at the moment marking a rise of 9.70% from the last ...

Most Recent

Market Summary

Should investors be concerned about IMRX’s high price-to-sales ratio?

Financial Scores

PM’s valuation metrics: A comprehensive analysis

Analyst Snapshot

How does BSY’s price to cash per share ratio compare in the market?

Stocks Trading

Analyzing DVAX’s price-to-book ratio for the last quarter

Market Summary

A closer look at STLD’s price-to-free cash flow ratio

Financial Scores

TSM’s price-to-sales ratio: Is it a good investment opportunity?

Who We Are

Fueled by a passion for truth since 1992, US Post News brings you trustworthy journalism. Our team of investigators, photographers, and writers delivers fresh news you can rely on. We started with ink and screens, but today we’re a web leader, illuminating the world with verified information.

Company

About US
Contact Us
Disclaimer
Privacy Policy

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Search for:

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies Enabled Disabled